Calamos Advisors
BSX icon

Calamos Advisors’s Boston Scientific BSX Stock Holding History

Calamos Advisors’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-285,000
Closed -$10.6M – 1295
2022
Q2 		$10.6M Buy
+285,000
New +$11.6M 0.05% 462

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Calamos Advisors's BSX Position: Q2 2026 in Review

Calamos Advisors reduced its Boston Scientific (BSX) stake by 17% in Q2 2026, selling an estimated $7.63M and leaving 677,114 shares worth $28.9M. The position accounts for 0.1% of the portfolio, ranked #209.

Calamos Advisors first reported a position in BSX in Q3 2019 and has held it in 28 quarters since. The position peaked at $107M in Q2 2025. 1,477 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Calamos Advisors held 677,114 shares of Boston Scientific worth $28.9M as of Q2 2026.
  • Calamos Advisors sold 140,572 Boston Scientific shares in Q2 2026, an estimated $7.63M.
  • Boston Scientific made up 0.1% of Calamos Advisors's portfolio in Q2 2026, its #209 holding.
  • Calamos Advisors first reported a position in Boston Scientific in Q3 2019 and has held it in 28 quarters since.
  • Calamos Advisors's Boston Scientific position peaked at $107M in Q2 2025.
  • 1,477 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.